Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Fasan, Annette ^a   Alpermann, Tamara ^a   Haferlach, Claudia ^a   Grossmann, Vera ^a   Roller, Andreas ^a   Kohlmann, Alexander ^a   Eder, Christiane ^a   Kern, Wolfgang ^a   Haferlach, Torsten ^a   Schnittger, Susanne ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; MESSENGER RNA; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CCAAT ENHANCER BINDING PROTEIN ALPHA GENE; CELL STRUCTURE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLT3 GENE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IDH2R140 GENE; IMMUNOPHENOTYPING; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHYLATION; NPM1 GENE; ONCOGENE; OUTCOME ASSESSMENT; PROMOTER REGION; RUNX1 GENE; TET2 GENE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEINS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION RATE; NUCLEAR PROTEINS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84873266709     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054365     Document Type: Article

References (30)

1. Koschmieder S, Halmos B, Levantini E, Tenen DG, (2009) Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 27: 619-628.
2. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, et al. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27: 263-270.
3. Snaddon J, Smith ML, Neat M, Cambal-Parrales M, xon-McIver A, et al. (2003) Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 37: 72-78.
4. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
5. Timchenko N, Wilson DR, Taylor LR, Abdelsayed S, Wilde M, et al. (1995) Autoregulation of the human C/EBP alpha gene by stimulation of upstream stimulatory factor binding. Mol Cell Bio 15: 1192-1202.
6. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, et al. (2006) Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98: 396-406.
7. Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, et al. (2007) Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 67: 4657-4664.
8. Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, et al. (2009) Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 124: 827-833.
9. Chim CS, Wong AS, Kwong YL, (2002) Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol 119: 988-990.
10. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, et al. (2007) Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 110: 3706-3714.
11. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, et al. (2008) Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 68: 3142-3151.
12. Lin TC, Hou HA, Chou WC, Ou DL, Yu SL, et al. (2011) CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia 25: 32-40.
13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC).
14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33: 451-458.
15. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman J, et al. (2008) Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.Lyon: International Agency for Research on Cancer (IARC). p. 110-23.
16. Haferlach T, Kern W, Schoch C, Hiddemann W, Sauerland MC, (2003) Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia. J Clin Oncol 21: 3004-3005.
17. ISCN (1995) Guidelines for cancer cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. F. Mitelman, S. Karger ed.
18. Grimwade D, Hills RK (2009) Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program: 385-395.
19. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, et al. (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104: 3078-3085.
20. Jost E, do ON, Wilop S, Herman JG, Osieka R, et al. (2009) Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia. Leuk Res 33: 443-449.
21. Tost J, Gut IG, (2007) DNA methylation analysis by pyrosequencing. Nat Protoc 2: 2265-2275.
22. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, et al. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100: 59-66.
23. Kohlmann A, Haschke-Becher E, Wimmer B, Huber-Wechselberger A, Meyer-Monard S, et al. (2008) Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study. Clin Chem 54: 1705-1715.
24. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Stat Soc B 57: 289-300.
25. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, et al. (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21: 4642-4649.
26. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, et al. (2011) Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 25: 1297-1304.
27. Hollink IH, Van den Heuvel-Eibrink MM, rentsen-Peters ST, Zimmermann M, Peeters JK, et al. (2011) Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 96: 384-392.
28. Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, et al. (2009) Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 113: 2795-2804.
29. Barjesteh van Waalwijk van Doorn-Khosrovani, Erpelinck C, Meijer J, van OS, van Putten WL, et al. (2003) Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4: 31-40.
30. Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, et al. (2010) Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 24: 1216-1220.